Sanofi

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3

15 December 2025

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

All figures current as of the U.S. market close on Friday, November 21, 2025. NVAX will next trade when markets reopen on Monday, November 24, 2025. Quick snapshot for NVAX heading into November 24, 2025 Novavax stock price today: where

24 November 2025

Biotech News · Financial Analysis · Investing · Novavax · Stock Market

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

What happened today Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the

6 November 2025

Biotechnology · Earnings Reports · Healthcare Industry · Pharmaceuticals · Stock Market